Lower cognitive performance in healthy G2019S LRRK2 mutation carriers

Neurology. 2012 Sep 4;79(10):1027-32. doi: 10.1212/WNL.0b013e3182684646. Epub 2012 Aug 22.

Abstract

Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene.

Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale.

Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007).

Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cognition / physiology*
  • Executive Function / physiology*
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Heterozygote*
  • Humans
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Male
  • Middle Aged
  • Mutation*
  • Neuropsychological Tests
  • Protein-Serine-Threonine Kinases / genetics*

Substances

  • LRRK2 protein, human
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Protein-Serine-Threonine Kinases